WP1066, a STAT3 pathway inhibitor, can penetrate the blood–brain barrier and is currently undergoing phase I clinical trials for adult recurrent glioma, metastatic melanoma, and high‐grade pediatric brain tumors.31 The gene discussed is STAT3; the disease is brain neoplasm.